Literature DB >> 12621350

Management of intratemporal facial nerve schwannoma.

Chong-Sun Kim1, Sun O Chang, Seung Ha Oh, Soon-Hyun Ahn, Chan Ho Hwang, Hyo Jeong Lee.   

Abstract

OBJECTIVE: The aim of this study was to report a series of 18 facial nerve schwannomas, including 2 infantile cases. STUDY
DESIGN: Retrospective case review.
SETTING: Tertiary referral center. PATIENTS: Eighteen patients with facial nerve schwannoma, operated on between 1980 and 2000. INTERVENTION: Surgical treatments were performed in all cases. MAIN OUTCOME MEASURES: The presenting symptoms and facial nerve function were graded using the House-Brackmann scale and eye closure. RESULTS Facial nerve paralysis was the most common symptom, presenting in 94% of cases, followed by hearing loss and mass lesion. In one case, the tumor was shaved, leaving the facial nerve intact. In the other cases, the facial nerve reconstruction with hypoglossal-facial anastomosis or interposition graft was performed. The postoperative facial function was House-Brackmann grade IV in most cases (88.2%). In terms of the functional recovery classified by complete or incomplete eye closure, the moderate preoperative facial nerve palsy group showed a better functional outcome than severe group.
CONCLUSION: In cases with good facial nerve function, it would be better to consider an alternative method for preserving the facial nerve. Furthermore, when facial nerve paralysis has developed to more than House-Brackmann grade III, an immediate operation is recommended to obtain a good postoperative facial functional recovery.

Entities:  

Mesh:

Year:  2003        PMID: 12621350     DOI: 10.1097/00129492-200303000-00030

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  1 in total

1.  Detection of the Moment of Nerve Decompression Using Continuous Monitoring of Evoked Facial Nerve Electromyograms in a Patient with Facial Nerve Schwannoma: Case Report.

Authors:  Asuka Nakazaki; Shigeru Yamaguchi; Hiroaki Motegi; Yukitomo Ishi; Michinari Okamoto; Miki Fujimura
Journal:  NMC Case Rep J       Date:  2022-07-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.